Key result
Adding etoricoxib to aspirin for 7 days significantly reduced TXM excretion and serum TXB(2) by approximately 25% in patients with essential thrombocythemia.
Why the study?
Does adding etoricoxib to aspirin reduce persistent thromboxane biosynthesis in patients with essential thrombocythemia?
RCT (n=65)
randomized
Does adding etoricoxib to aspirin reduce persistent thromboxane biosynthesis in patients with essential thrombocythemia?
Answers are grounded in this paper and cite their sources.
We tested whether cyclooxygenase 2 (COX-2) expression and unacetylated COX-1 in newly formed platelets might contribute to persistent thromboxane (TX) biosynthesis in aspirin-treated essential thrombocythemia (ET). Forty-one patients on chronic aspirin (100 mg/day) and 24 healthy subjects were studied. Platelet COX-2 expression was significantly increased in patients and correlated with thiazole orange-positive platelets (r = 0.71, P < .001). The rate of TXA(2) biosynthesis in vivo, as reflected by urinary 11-dehydro-TXB(2) (TXM) excretion, and the maximal biosynthetic capacity of platelets, as reflected by serum TXB(2), were higher in patients compared with aspirin-treated healthy volunteers. Serum TXB(2) was significantly reduced by the selective COX-2 inhibitor NS-398 added in vitro. Patients were randomized to adding the selective COX-2 inhibitor, etoricoxib, or continuing aspirin for 7 days. Etoricoxib significantly reduced by approximately 25% TXM excretion and serum TXB(2). Fourteen of the 41 patients were studied again 21 (+/- 7) months after the first visit. Serum TXB(2) was consistently reduced by approximately 30% by adding NS398 in vitro, while it was completely suppressed with 50 microM aspirin. Accelerated platelet regeneration in most aspirin-treated ET patients may explain aspirin-persistent TXA(2) biosynthesis through enhanced COX-2 activity and faster renewal of unacetylated COX-1. These findings may help in reassessing the optimal antiplatelet strategy in ET.
No takes yet. Share an insight, caveat, or question.
Dragani et al. (2009) conducted an RCT in Essential thrombocythemia (n=65). Etoricoxib vs. Continuing aspirin was evaluated on Urinary 11-dehydro-TXB(2) (TXM) excretion and serum TXB(2). Adding etoricoxib to aspirin for 7 days significantly reduced TXM excretion and serum TXB(2) by approximately 25% in patients with essential thrombocythemia.
Synapse has enriched 10 related papers. Consider them for comparative context: